Sphingolipid and Ceramide Metabolism

Ceramides are a family, not a compound.

Three Routes to Ceramide

RouteEnzymesTimescaleProduct profile
De novoSPT (SPTLC1/2/3) → 3-ketosphinganine → sphinganine → dihydroceramide (CerS) → ceramide (DES)HoursDetermined by the CerS isoform expressed
SalvageCeramide synthases re-acylate sphingosine from sphingolipid breakdownMinutes to hoursReflects the sphingosine pool
SphingomyelinaseSMPD1 (acid), SMPD2/3 (neutral) hydrolyse sphingomyelinMinutesSphingomyelin-derived species

Important distinction. The de novo route and the sphingomyelinase route produce ceramide with different acyl chains and in different compartments. Acid sphingomyelinase acts in lysosomes and at the plasma membrane; the de novo route acts in the ER. A "ceramide increase" measured in a whole-cell extract cannot distinguish them, and the two have different downstream consequences.

Part 1 — The CerS Isoforms

IsoformMain productTissueNote
CerS1C18:0Brain, skeletal muscleLess studied in metabolic disease
CerS2C22–C24Liver, kidneyVery-long-chain; membrane structural role
CerS4C18–C22Skin, others
CerS5C16UbiquitousContributes to C16 alongside CerS6
CerS6C16Ubiquitous, high in metabolic tissuesThe isoform most consistently linked to metabolic injury

Caveat on the C16 story. CerS6 deletion protects against diet-induced metabolic injury in mouse models, and the genetic evidence is stronger than the pharmacological evidence. But CerS5 also produces C16 ceramide, so a CerS6 knockout reduces rather than eliminates the species; total C16 measurement will show a partial effect, and severity of the phenotype may not scale with the residual.

Part 2 — What Each Inhibitor Does

AgentTargetEffectLimitation
MyriocinSerine palmitoyltransferaseReduces all de novo sphingolipidsNot ceramide-specific; affects glycosphingolipids and sphingomyelin too
Fumonisin B1Ceramide synthasesAccumulates sphinganine; reduces complex sphingolipidsSphinganine is itself bioactive; broad isoform inhibition
GW4869Neutral sphingomyelinase 2Reduces sphingomyelin-derived ceramidePoor solubility; extracellular vesicle effects
Desipramine, amitriptylineAcid sphingomyelinaseReduces lysosomal ceramideAntidepressant off-target effects at effective doses
CerS6 knockdownOne isoformSelective reduction of C16Incomplete; compensation by CerS5

Readout note. Fumonisin's accumulation of sphinganine is not a side note; it is a mechanism. Studies using fumonisin to "lower ceramide" may be producing a sphinganine-mediated phenotype, and the interpretation requires measuring both species.

Part 3 — Measurement

MethodWhat it reportsRequirement
LC-MS/MS with class-specific internal standardsIndividual species, quantitativeIsotope-labelled standards; species separation
LC-MS without internal standardsRelative speciesComparability within a run only
TLC after lipid extractionClass-levelHistorical; low resolution
Antibody-based "ceramide" assaysBulk signalNot species-resolved; cross-reactivity
Sphingolipid panel kitsSeveral classesVerify species coverage and standards

Important distinction. A total ceramide value is a sum over species that have different physical properties and different biological effects. Reporting it is analogous to reporting total amino acids: technically reproducible, biologically uninformative.

The quantitative standard is a targeted LC-MS/MS panel with isotope-labelled internal standards for each class, reporting at least C14, C16, C18, C20, C22, C24:0 and C24:1, plus dihydroceramides and sphingosine/sphinganine. This is now routine in specialist laboratories and is the difference between a ceramide claim that survives review and one that does not.

Part 4 — Which Ceramide Claim Is Which

ClaimMinimum evidenceWhat does not count
"Ceramide increased"Species-resolved quantification, at least C16 and C18 separatelyTotal ceramide
"De novo synthesis increased"Serine or palmitate labelling into ceramide; SPT dependenceIncreased CerS expression
"Ceramide mediates the phenotype"Isoform-specific genetic perturbation plus rescue, or a species-specific manipulationCorrelation between ceramide and viability
"CerS6-derived C16 is responsible"CerS6 loss with residual species measured, plus a C16-specific rescueTotal ceramide reduction

The third row is the difficult one, because there is no clean way to add back a specific ceramide species to a cell. The available approaches are limited: short-chain ceramide analogues (C2, C6) do not partition like endogenous species; ceramide delivery by albumin or liposomes is imprecise. This is why the strongest ceramide papers rely on genetic manipulation of the synthetic route and accept that the rescue is partial.

Part 5 — Model Requirements and Recurring Failures

RequirementWhy
Serum recordedSerum contains sphingolipids and lipoproteins
Fatty acid supply definedPalmitate is the substrate for de novo synthesis
Serine availability recordedSerine restriction reduces de novo synthesis independently
Species panel reportedChain length is the variable
Dihydroceramide measuredDES activity affects the dihydroceramide/ceramide ratio
Timepoint matched to the routeSphingomyelinase acts in minutes; de novo in hours

Recurring failures:

  • • Total ceramide reported as the finding.
  • • Fumonisin used as a ceramide-lowering tool without measuring sphinganine.
  • • Myriocin described as a ceramide inhibitor, when it blocks all de novo sphingolipids.
  • • Short-chain ceramide analogues treated as equivalent to endogenous species.
  • • CerS expression reported as synthesis rate.
  • • Serine supply unrecorded in a de novo synthesis claim.
  • • Single timepoint that cannot distinguish the sphingomyelinase and de novo routes.

Part 5 — Structural Versus Signalling Ceramide

The same molecule serves two roles, and they are measured and interpreted differently.

RoleWhereHow it is studiedEvidence standard
StructuralMembranes; very-long-chain speciesLipidomics; membrane order; permeabilityComposition and physical measurement
SignallingMicrodomains; enzyme recruitmentCo-localisation with signalling proteins; PP2A activationSpatial and functional

Important distinction. Structural ceramide is abundant and changes slowly; signalling ceramide is a small, compartmentalised pool that can change rapidly without a measurable change in total. A whole-cell lipidomics experiment is well suited to the first and poorly suited to the second, because the signalling pool is a small fraction of the total and is averaged over all membranes.

This is the reason some of the strongest ceramide signalling papers use spatially resolved methods — tagged ceramide-binding domains, or ceramide antibodies validated against a ceramide-deficient background — while some of the strongest metabolic papers use bulk lipidomics. The two literatures describe different pools, and a claim should say which one it concerns.

A practical consequence for design: if the phenotype appears within minutes, it is unlikely to be explained by a change in bulk ceramide, which requires de novo synthesis over hours. Timecourse and route-specific inhibition together identify which pool moved.

Part 6 — Where This Article Connects

Ceramide is one of the toxic species in the lipid pillar, and it sits at the intersection of the sphingolipid module, the fatty acid supply (palmitate and serine are its substrates), and membrane composition through sphingomyelin. The ceramide detection article in this cluster covers the analytical detail; the phospholipid article covers the membrane context in which ceramide acts.

If you need species-resolved sphingolipid measurement with isoform-specific perturbations, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Ceramide species distribution, CerS isoform expression and the balance between routes vary with cell type, substrate supply and stimulus. The associations described here are context-dependent.

A change in total ceramide does not establish which species changed, and a change in a species does not establish that it mediated the phenotype.

Scientific interpretation and experimental design

  • • Species, not totals. Chain length is the biological variable.
  • • Three routes, three compartments. Whole-cell extracts merge them.
  • • Fumonisin accumulates sphinganine. Measure it.
  • • Myriocin blocks the whole pathway. Not ceramide-specific.
  • • Genetic isoform loss is stronger evidence than pharmacology.
  • • Short-chain analogues are not endogenous species.
  • • Substrates matter. Palmitate and serine set the rate.

Selected references for further reading

  • • Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nature Reviews Molecular Cell Biology. 2018;19:175–191.
  • • Turpin-Nolan SM, et al. CerS6-derived C16:0 ceramide promotes the development of obesity and insulin resistance. Cell Metabolism. 2020;31:1–14.
  • • Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides in insulin resistance. Nature Metabolism. 2019;1:1051–1064.
  • • Merrill AH Jr, et al. Sphingolipid analysis by HPLC–tandem mass spectrometry. Methods in Enzymology. 2005;393:224–243.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: